Sperm Bank, Inc. dba Fertility Center of California
Letter data
- Company
- Sperm Bank, Inc. dba Fertility Center of California
- Recipient
- Martin D. Bastuba, M.D. | Owner/Medical Director | Sperm Bank, Inc. dba Fertility Center of California | 6699 Alvarado Road, Suite 2208 | San Diego | , | CA | 92120 | United States | Director@fertilityCTR.com
- Issue date
- 2026-02-09
- Posted date
- Not available
- FDA office
- Center for Biologics Evaluation and Research (CBER)
- Subject
- Not available
- Product
- Biologics
- CMS ID
- 694273
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Sperm Bank, Inc. dba Fertility Center of California
MARCS-CMS 694273 —
February 09, 2026
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
Via Email
Product:
Biologics
Recipient:
Recipient Name
Martin D. Bastuba, M.D.
Recipient Title
Owner/Medical Director
Sperm Bank, Inc. dba Fertility Center of California
6699 Alvarado Road, Suite 2208
San Diego
,
CA
92120
United States
Director@fertilityCTR.com
Issuing Office:
Center for Biologics Evaluation and Research (CBER)
United States
Secondary Issuing Offices
United States
Dear Dr. Bastuba:
The Food and Drug Administration has completed evaluation of your corrective actions in response to our Warning Letter CBER 25-694273 dated February 14, 2025. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Act(s) and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Melissa J. Mendoza
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research
Content current as of:
02/19/2026
Regulated Product(s)
Biologics